location: Current position: Home >> Scientific Research >> Paper Publications

Studies on in vitro release performance of hydrophilic drugs and lipophilic drugs in amphiphilic SIS-based hot-melt pressure sensitive adhesives

Hits:

Indexed by:期刊论文

Date of Publication:2013-07-13

Journal:Applied Mechanics and Materials

Included Journals:EI、CPCI-S、Scopus

Volume:395-396

Page Number:389-398

ISSN No.:9783037858424

Key Words:pressure-sensitive; infrared spectra; adhesion; transdermal; drug release

Abstract:In order to fabricate a kind of amphiphilic hot-melt pressure sensitive adhesives (HMPSAs) suitable for transdermal drug delivery systems (TDDS) of natural medicines, SIS-based hot-melt pressure sensitive adhesives were modified by a melt-blending method, in which a kind of hydrophilic poly (ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl methacrylate chloride) (RLPO) and polyethylene glycol 2000 (PEG2000) were utilized. Functional RLPO and its plasticizer PEG2000 worked as a hydrophilic skeleton of amphiphilic HMPSAs. SEM and FT-IR results indicated that RLPO and SIS were partially compatible with each other through n-pi complex between the n electrons of the carbonyl group of RLPO and the it electrons of the benzene rings of SIS and their compound had a good thermal stability. The phase microscope images showed that PEG could improve the compatibility between RLPO phase and SIS phase. As the ratio of SIS/RLPO/PEG equaled to 1/2/1.6, their compounds obtained bi-continuous structures. Geniposide (logP<0) and oleanic acid (logP=9.0) were chosen as representatives of hydrophilic drugs and lipophilic drugs, respectively. It was observed that both hydrophilic drugs and lipophilic drugs had a continuous release in the optimized amphiphilic HMPSAs. In addition, the release behavior of hydrophilic geniposide could be controlled by adjusting the ratio of RLPO to PEG.

Pre One:A Potential Mechanism of a Cationic Cyclopeptide for Enhancing Insulin Delivery across Caco-2 Cell Monolayers

Next One:Selective Inhibition of Bicyclic Tetrapeptide Histone Deacetylase Inhibitor on HDAC4 and K562 Leukemia Cell